NASDAQ · CDNA
Healthcare · Medical - Diagnostics & Research
$53.55
Up+$0.91 (+1.73%)
Updated Sep 17, 2026, 11:07 AM
SID Score
6.3/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
CDNA closed at $53.55 after 20 trading sessions, up 15.14% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 16, 2026 | $52.61 | $54.488 | $52.61 | $53.55 | 846.28K |
| Sep 15, 2026 | $52.20 | $53.74 | $51.7301 | $52.64 | 950.02K |
| Sep 14, 2026 | $50.49 | $52.67 | $50.17 | $52.37 | 795.53K |
| Sep 11, 2026 | $50.14 | $50.85 | $49.57 | $50.26 | 663.05K |
| Sep 10, 2026 | $49.19 | $51.69 | $48.64 | $50.02 | 1.61M |
| Sep 9, 2026 | $49.875 | $51.33 | $49.64 | $50.03 | 1.22M |
| Sep 8, 2026 | $50.50 | $50.87 | $49.46 | $50.31 | 935.08K |
| Sep 4, 2026 | $49.65 | $50.99 | $48.68 | $50.88 | 1.31M |
| Sep 3, 2026 | $49.75 | $50.50 | $48.3856 | $49.86 | 636.77K |
| Sep 2, 2026 | $49.55 | $51.37 | $48.40 | $49.60 | 826.21K |
| Sep 1, 2026 | $49.93 | $50.62 | $48.2501 | $48.97 | 1.25M |
| Aug 31, 2026 | $49.16 | $50.28 | $46.6879 | $50.11 | 1.53M |
| Aug 28, 2026 | $51.495 | $52.38 | $49.60 | $49.79 | 1.18M |
| Aug 27, 2026 | $51.00 | $53.6712 | $50.765 | $52.36 | 1.25M |
| Aug 26, 2026 | $50.15 | $51.08 | $49.0666 | $50.96 | 1.42M |
| Aug 25, 2026 | $48.13 | $51.125 | $47.234 | $50.80 | 1.79M |
| Aug 24, 2026 | $48.30 | $48.51 | $46.92 | $47.50 | 769.59K |
| Aug 21, 2026 | $46.99 | $48.72 | $46.0497 | $48.61 | 1.16M |
| Aug 20, 2026 | $45.902 | $47.845 | $45.332 | $46.99 | 911.18K |
| Aug 19, 2026 | $46.85 | $48.4299 | $46.41 | $46.51 | 1.89M |
The latest Smart Investors Daily articles mentioning CDNA.
CDNA research
Company profile and research snapshot.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 2, 2026 | Canaccord Genuity | Buy | — |
| Aug 6, 2026 | BTIG | Buy | — |
| Jul 31, 2026 | HC Wainwright & Co. | Neutral | — |
| Jul 16, 2026 | BTIG | Buy | — |
| Apr 29, 2026 | BTIG | Buy | — |
No generated briefing is available yet.
ChartMill · Sep 10, 2026
CAREDX (CDNA) clears Minervini Trend Template with high-growth momentum, strong RS, and a near-high breakout setup, but disciplined risk controls remain.
Yahoo · Sep 8, 2026
Here is how CareDx (CDNA) and Concentra Group (CON) have performed compared to their sector so far this year.
ChartMill · Sep 5, 2026
CareDx (CDNA) shows high growth momentum with accelerating sales and earnings, plus a 10 technical rating. Breakout setup near $53.68.
Benzinga · Sep 2, 2026
Canaccord Genuity analyst Kyle Mikson initiates coverage on CareDx (NASDAQ:CDNA) with a Buy rating and announces Price Target of $65.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CDNA.
